Host: Tracey Evans, MD

Guest: Raja Mudad, MD

For thirty years, there were limited therapeutic advancements leading to FDA approvals in extensive-stage small cell lung cancer (ES-SCLC). However, this all changed with the IMpower133 trial, which led to the emergence of immunotherapy as a first line treatment option in ES-SCLC. Joining Dr. Tracey Evans is medical oncologist Dr. Raja Mudad to discuss the IMpower133 trial and the reasons to consider TECENTRIQ® (atezolizumab), the first immunotherapy combination for patients with ES-SCLC.

This program is intended for US Physicians.

M-US-00010808(v1.0)